Lark Health and Samsung unite to scale AI chronic care for US seniors

Lark Health, an AI-powered chronic disease management platform, and Samsung Electronics have announced a multi-year strategic partnership that will embed Lark's health coaching programmes directly into Samsung Health, the tech giant's consumer wellness app. Rolling out from Q3 2026, the tie-up targets the roughly half of American seniors eligible for Medicare, offering AI-guided care for conditions including prediabetes, diabetes, hypertension, and stress at no out-of-pocket cost.

The partnership is notable less for the technology involved than for the distribution architecture it unlocks. Samsung's hardware footprint spans more than 400 million devices globally, including the Galaxy Watch and Galaxy Ring wearables. By embedding Lark's coaching layer into that ecosystem, the companies are effectively turning consumer electronics into a federally reimbursed primary-care adjacent channel, something no payer-sponsored digital health initiative has previously achieved at comparable scale.

Leveraging Medicare reimbursement as a distribution engine

Three distinct programme tiers will be available depending on eligibility. All Samsung Health users aged 65 and over gain access to Lark Prevention, a wellness programme covering sleep, nutrition, exercise, and tobacco cessation. Qualifying seniors at risk of type 2 diabetes can enrol in Lark's CDC-recognised Medicare Diabetes Prevention Programme (MDPP), which includes a connected smart scale, at no additional cost. The most clinically intensive tier, Lark Medicare ACCESS, pairs AI coaching with clinical oversight from Lark's affiliated medical group, supplying blood pressure cuffs and glucometers and sharing care coordination data with the member's primary care clinician electronically.

The ACCESS tier is significant because it routes through the Centers for Medicare and Medicaid Services' Medicare Advancing Chronic Care with Effective, Scalable Solutions model, a federal initiative designed to shift chronic disease management from episodic, clinic-based encounters toward continuous, home-based monitoring. For Lark, CMS approval as an ACCESS provider converts the platform from a direct-to-consumer wellness app into a billable clinical entity operating inside the US federal payer system, a regulatory boundary that most digital health companies have struggled to cross.

"By embedding Lark's AI-powered health coaching within Samsung Health, we're giving seniors everywhere direct access to clinically validated programmes on the Galaxy devices they already own and use every day," said Dr. Hon Pak, Senior Vice President and Head of the Digital Health Team at Samsung Electronics.

Convergence read-across: consumer hardware as healthcare infrastructure

The Lark-Samsung deal crystallises a convergence trend that has been building quietly at the intersection of consumer electronics, federal payer systems, and AI clinical validation. For strategic investors watching the wellbeing and healthtech space, the structural shift is this: the reimbursement gateway into 65-million-strong Medicare populations is no longer exclusively controlled by hospital networks or pharmacy benefit managers. A consumer device maker with sufficient reach and a clinically validated AI partner can now route around those incumbents entirely.

This has meaningful implications for the broader internet-of-things and connected-device market. Wearable and ambient sensor makers, from CGM (continuous glucose monitor) manufacturers to smart-home sensor platforms, face a clearer commercial pathway if they can demonstrate integration with federally reimbursed care pathways. The Lark model, built on more than $180 million in R&D and validated across 22 peer-reviewed studies, offers a template: accumulate clinical evidence, secure CMS programme approval, then attach to a hardware distribution network at scale.

For capital allocators, the deal also signals continued institutional appetite for AI-native platforms that sit at the boundary of consumer and clinical health. The wellbeing-to-clinical continuum is attracting sovereign and institutional capital precisely because federal reimbursement de-risks revenue at scale. Whether the Lark-Samsung model proves replicable, or whether Samsung's consumer health ambitions extend further into clinical AI partnerships, will be closely watched as the ACCESS model's early cohort data emerges in 2027.